Literature DB >> 2540772

An enzyme-linked immunosorbent assay for antibodies to the envelope glycoproteins of divergent strains of HIV-1.

J P Moore1, L A Wallace, E A Follett, J A McKeating.   

Abstract

We have developed an enzyme-linked immunosorbent assay (ELISA) specific for antibodies to the envelope glycoproteins gp120 and gp160 of HIV-1. An antibody to a conserved epitope on gp120 is adsorbed to a solid phase and used to capture gp120 and/or gp160 from solution. This may be purified recombinant protein or in simple, non-denaturing detergent extracts of different strains of HIV-1. Human serum antibodies bound to the captured antigen are subsequently detected with an anti-human antibody conjugated to alkaline phosphatase, and the AMPAK ELISA amplification system (Novo BioLabs, Cambridge, UK). With this procedure, antibodies can be detected that recognize gp120 from a wide range of divergent HIV-1 strains. The ELISA is sufficiently sensitive to detect env antibodies in sera from HIV-positive individuals at dilutions of 1:300,000. No repeatable false-positives were detected in a screen of 250 normal serum samples. Env antibodies were detected in all 37 strongly HIV-positive sera tested, and in four sera that were borderline or weakly positive in commercial ELISA. However, 55 sera positive in commercial ELISA but unconfirmable by Western blot ('ambiguously' positive) did not contain detectable env antibodies.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2540772     DOI: 10.1097/00002030-198903000-00006

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  34 in total

1.  Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo.

Authors:  Y Ye; Z H Si; J P Moore; J Sodroski
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding.

Authors:  Pin-Fang Lin; Wade Blair; Tao Wang; Timothy Spicer; Qi Guo; Nannan Zhou; Yi-Fei Gong; H-G Heidi Wang; Ronald Rose; Gregory Yamanaka; Brett Robinson; Chang-Ben Li; Robert Fridell; Carol Deminie; Gwendeline Demers; Zheng Yang; Lisa Zadjura; Nicholas Meanwell; Richard Colonno
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-20       Impact factor: 11.205

3.  BLT-humanized C57BL/6 Rag2-/-γc-/-CD47-/- mice are resistant to GVHD and develop B- and T-cell immunity to HIV infection.

Authors:  Kerry J Lavender; Wendy W Pang; Ronald J Messer; Amanda K Duley; Brent Race; Katie Phillips; Dana Scott; Karin E Peterson; Charles K Chan; Ulf Dittmer; Timothy Dudek; Todd M Allen; Irving L Weissman; Kim J Hasenkrug
Journal:  Blood       Date:  2013-09-10       Impact factor: 22.113

4.  Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection.

Authors:  Yongjun Guan; Mohammad M Sajadi; Roberta Kamin-Lewis; Timothy R Fouts; Anthony Dimitrov; Zhixin Zhang; Robert R Redfield; Anthony L DeVico; Robert C Gallo; George K Lewis
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-18       Impact factor: 11.205

5.  Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization.

Authors:  J A McKeating; A McKnight; J P Moore
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

6.  Comparison of intradermal and intramuscular delivery followed by in vivo electroporation of SIV Env DNA in macaques.

Authors:  Viraj Kulkarni; Margherita Rosati; Jenifer Bear; Guy R Pilkington; Rashmi Jalah; Cristina Bergamaschi; Ashish K Singh; Candido Alicea; Bhabadeb Chowdhury; Gen-Mu Zhang; Eun-Young Kim; Steven M Wolinsky; Wensheng Huang; Yongjun Guan; Celia LaBranche; David C Montefiori; Kate E Broderick; Niranjan Y Sardesai; Antonio Valentin; Barbara K Felber; George N Pavlakis
Journal:  Hum Vaccin Immunother       Date:  2013-06-28       Impact factor: 3.452

7.  IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques.

Authors:  Rashmi Jalah; Vainav Patel; Viraj Kulkarni; Margherita Rosati; Candido Alicea; Brunda Ganneru; Agneta von Gegerfelt; Wensheng Huang; Yongjun Guan; Kate E Broderick; Niranjan Y Sardesai; Celia LaBranche; David C Montefiori; George N Pavlakis; Barbara K Felber
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

8.  Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies.

Authors:  J P Moore; F E McCutchan; S W Poon; J Mascola; J Liu; Y Cao; D D Ho
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

9.  A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B.

Authors:  J P Moore; A Trkola; B Korber; L J Boots; J A Kessler; F E McCutchan; J Mascola; D D Ho; J Robinson; A J Conley
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

10.  Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding.

Authors:  L Stamatatos; C Cheng-Mayer
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.